Your browser does not support java script. Skip navigation
Loading, please wait  Loading, please wait...

The Management of Treatment Resistant Depression: The Art and Science



Charles Nemeroff, M.D., Ph.D.
Chair and Professor
Department of Psychiatry
The University of Texas at Austin Dell School of Medicine

Learning Objectives
  • Explain the latest treatment advances and research findings for treatment- resistant depression (TRD)
  • Describe the emerging strategies in the use of atypical antipsychotics and new agents in the treatment of TRD
  • Demonstrate the integration of appropriate psychopharmacologic treatments into a comprehensive treatment plan, including cognitive and behavioral psychotherapies
  • Discuss the evidence for the following agents in the management of TRD: Ketamine, rTMS, ECT, and DBS

Activity Description

This program consists of 1 video and downloadable resources in PDF format.  To begin, take the ungraded pre-test for the first module below.  Review the video and handouts, then complete the post-test ( > 70% within 5 attempts) and evaluation. CPE credit will automatically upload to CPE Monitor (allow 7 days). 
 

Continuing Education Credit
 
The University of Texas at Austin College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  This online activity is approved for 0.10 CEUs (1.00 contact hour) of continuing education credit. In order to receive 1.00 contact hour of CE credit, the participant must complete the online pre-test (ungraded), watch the included video in its entirety, pass the online post-test ( > 70% within 5 attempts), and complete the online evaluation.  Upon successful completion of the course evaluation, continuing pharmacy education credits will automatically be uploaded to CPE Monitor (allow 7 days). 
Please make sure NABP profile ID and date of birth (month/year) are entered correctly under learner's profile in this system.
 

 

Fee

$25.00

CE Hours

1.00

CE Units

0.100

Activity Type

  • Knowledge

Target Audience(s)

  • Pharmacists

 

 

 

The Management of Treatment Resistant Depression: The Art and Science

About the Faculty

Charles Nemeroff, M.D., Ph.D.
Chair and Professor
Department of Psychiatry
The University of Texas at Austin Dell School of Medicine

Charles Nemeroff is chair and professor with the Department of Psychiatry and BehavioralSciences. He also directs the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences.Prior to joining Dell Med, Nemeroff was chair of the Department of Psychiatry and BehavioralSciences and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine in Miami, Florida.He received his medical degree and doctorate degrees in neurology from the University of NorthCarolina (UNC) School of Medicine. After psychiatry residency training at UNC and DukeUniversity, he held faculty positions at Duke and at Emory University before relocating to theUniversity of Miami in 2009.He has served as president of the American College of Psychiatrists (ACP) and the American College of Neuropsychopharmacology (ACNP), and sits on the Scientific Advisory Board and board of directors of the American Foundation for Suicide Prevention (AFSP) and the Anxiety and Depression Association of America (ADAA).He has received a number of research and education awards including the Kempf Award inPsychobiology, the Samuel Hibbs Award, Research Mentoring Award, Judson Marmor Award and the Vestermark Award from the American Psychiatric Association (APA), the Mood Disorders Award, Bowis Award and Dean Award from the ACP and the Julius Axelrod Award for mentoring from the ACNP. He was elected to the National Academy of Medicine in 2002. He was also named Alumnus of the Year from the University of North Carolina and from the UNCMedical School. He received the Doctorate Honoris Causa from Maimonides University inBuenos Aires in 2015.He is a member of the APA Council on Research and Chairs both the APA ResearchColloquium for Young Investigators and the APA Work Group on Biomarkers and NovelTreatments.His research is focused on the pathophysiology of mood and anxiety disorders with a focus on the role of child abuse and neglect as a major risk factor. He has also conducted research on the role of mood disorders as a risk factor for major medical disorders including heart disease, diabetes and cancer. He has published more than 1,000 research reports and reviews, and his research is currently supported by grants from the National Institutes of Health.He has also served on the Mental Health Advisory Council of National Institute of Mental Health and the Biomedical Research Council for NASA; is co-editor in chief (with Alan F. Schatzberg,M.D.) of the Textbook of Psychopharmacology, published by the APA Press and now in its Fifth Edition; and is the co-editor in chief of a new journal published by Elsevier, PersonalizedMedicine in Psychiatry.

Disclosure:  Dr. Nemeroff has the following relevant financial relationships, potential orperceived, with commercial or conflicts of interest to disclose:Grant/Research Support: National Institutes of Health (NIH)Stock Shareholder: Xhale, Celgene, Seattle Genetics, Abbvie, OPKO Health, Inc.,Antares, BI Gen Holdings, Inc., Corcept TherapeConsultant: Xhale, Takeda, Taisho Pharmaceutical Inc.,Signant Health,, SunovionPharmaceuticals Inc., Janssen RBoard of Directors / Leadership Roles: Gratitude America, ADAA, Xhale Smart, Inc.American Foundation for Suicide Prevention (AFSP), Brain and Behavior ResearchFoundation (BBRF), Xhale, Anxiety Disorders Association of America (ADAA), SkylandTrail, Signant Health, Laureate Institute for Brain Research (LIBR), Inc.


 

Activity Number

0067-0000-20-107-H04-P

Release Date: Oct 15, 2020
Credit Expiration Date: Oct 15, 2022

CE Hours

1.00